Silence Therapeutics Q2 FY26 net loss narrows to $12.3 million; revenue falls to $0 from $224,000

Reuters2026/08/10 11:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Silence Therapeutics posted a Q2 net loss of USD 12.3 million, narrowing from USD 27.4 million a year earlier; loss per share improved to USD 0.09 from USD 0.19.
R&D expenses fell 48% to USD 9.1 million on zerlasiran Phase 3 readiness completion in 2025 and lower personnel costs.
G&A expenses edged down to USD 4.7 million from USD 5.1 million; cash and cash equivalents totaled USD 72.1 million at June 30.
Completed patient dosing in the Phase 2 SANRECO trial of divesiran in 48 phlebotomy-dependent polycythemia vera patients in June.
Phase 1 results for SLN312 (AZD1705) showed favorable safety with durable, dose-dependent ANGPTL3 reductions; preclinical programs SLN365 and SLN098 remain positioned for potential 2027 IND filings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silence Therapeutics plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202608100715BIZWIRE_USPR_____20260810_BW075814) on August 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Silence Therapeutics Q2 FY26 net loss narrows to $12.3 million; revenue falls to $0 from $224,000

You may also like

Crypto prices